Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Reuters

09/16

<a href="https://laohu8.com/S/CSBR">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year

Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2567426471"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567426471\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567426471?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 03:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567426471","market":"nz","top_or_hot":-1,"title":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChampions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-16 03:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CSBR\">Champions Oncology</a> Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSBR","symbol_name":"Champions Oncology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDLcgMh9k:1","article_id":"2567426471","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567426471","pubTimestamp":1757966121,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire  on September 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSBR":"Champions Oncology, Inc."},"translate_title":"Champions Oncology报告2026财年第一季度收入为1400万美元，调整后EBITDA为60,000美元；收入略低于去年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":0.9},"content_text":"Champions Oncology Reports $14 Million Revenue for Q1 FY 2026, Adjusted EBITDA at $60,000; Revenue Slightly Lower Than Last Year\n    \n\n        Champions Oncology Inc. reported its financial results for the first quarter of fiscal 2026, ending July 31, 2025. The company achieved total revenue of $14 million, marking a decrease from the previous year's first quarter, but showing sequential growth that met expectations. The company recorded an adjusted EBITDA of $59,000, down from $2.0 million in the first quarter of fiscal 2025. Champions reported a loss from operations of $527,000 compared to an income from operations of $1.3 million in the same period last year. David Miller, CFO of Champions Oncology, noted that the company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company also announced the appointment of Rob Brainin as Chief Executive Officer to lead the next phase of growth.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073466) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}